Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Announced promising preliminary clinical data for OTX-2002 from ongoing MYCHELANGELO™ I trial; clinical proof-of-platform established with potenti...

Related Keywords

Boston ,Massachusetts ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Michellec Werner ,Mahesh Karande ,Development Pipeline ,International Conference On Molecular ,Nasdaq ,Omega Therapeutics Inc ,Linkedin ,Rna Health Conference ,Chris Schade ,Chief Executive Officer ,Key Anticipated ,Molecular Targets ,Cancer Therapeutics ,Investigational New Drug ,American Association ,Liver Diseases ,Flagship Pioneering ,Best Places ,Private Securities Litigation Reform Act ,Quarterly Report ,Months Ended September ,